Streetbeat News

Earnings

CRNX

17 analysts have provided ratings for Crinetics Pharmaceuticals (NASDAQ:CRNX), with a mix of bullish and somewhat bullish perspectives. The average 12-month price target is $64.06, reflecting an 18.45% increase from the previous target. Despite positive analyst sentiment, the company faces financial challenges, including a significant revenue decline and negative profitability metrics.

Portfolio Pulse from Benzinga Insights

June 04, 2024 | 12:01 pm

PCOR

Analysts have provided mixed evaluations for Procore Technologies (NYSE:PCOR) over the past three months, with a recent trend towards lowering price targets. The average 12-month price target has decreased by 5.13% to $80.75. Key financial indicators show Procore facing challenges in profitability and asset utilization, despite notable revenue growth.

Portfolio Pulse from Benzinga Insights

June 04, 2024 | 12:00 pm

PTC

PTC (NASDAQ:PTC) has received mixed ratings from 7 analysts over the past three months, with a slight increase in the average 12-month price target. Analysts have adjusted their ratings and price targets based on recent developments, reflecting a range of perspectives from 'Neutral' to 'Outperform'. PTC's financial performance shows strong revenue growth and net margins but faces challenges with ROE and debt management.

Portfolio Pulse from Benzinga Insights

June 04, 2024 | 12:00 pm

HALO

8 analysts have shared their evaluations of Halozyme Therapeutics (NASDAQ:HALO) over the past three months, showing a mix of bullish and somewhat bullish perspectives. The average 12-month price target has decreased by 8.22% to $52.62. Key financial metrics indicate strong profitability and revenue growth, but the company faces challenges with high debt levels.

Portfolio Pulse from Benzinga Insights

June 04, 2024 | 12:00 pm

BARK

BARK shares are trading lower after the company reported worse-than-expected Q4 financial results and issued Q1 and FY25 revenue guidance below estimates.

Portfolio Pulse from Benzinga Newsdesk

June 04, 2024 | 11:56 am

TOUR

Tuniu shares are trading higher following the company's announcement of a year-over-year increase in Q1 revenue results and positive Q2 revenue guidance.

Portfolio Pulse from Benzinga Newsdesk

June 04, 2024 | 11:54 am

DCI

Donaldson shares are trading higher after the company reported better-than-expected Q3 earnings and raised its FY24 guidance.

Portfolio Pulse from Benzinga Newsdesk

June 04, 2024 | 11:38 am

CNM

Core & Main has raised its fiscal 2024 outlook, now expecting net sales of $7.5B-$7.6B and Adjusted EBITDA of $935M-$975M, reflecting recent acquisitions and strong first-quarter performance. The company anticipates solid end market demand and low single-digit sales growth, excluding acquisitions.

Portfolio Pulse from Benzinga Newsdesk

June 04, 2024 | 11:38 am

BBIO

BridgeBio Pharma (NASDAQ:BBIO) announced positive Phase 2 results for its achondroplasia treatment, infigratinib, showing significant efficacy and safety. An investor call is scheduled for June 4, 2024, to discuss the results.

Portfolio Pulse from Benzinga Newsdesk

June 04, 2024 | 11:34 am

CNM

Core & Main (NYSE:CNM) reported Q1 earnings per share (EPS) of $0.49, missing the analyst estimate of $0.52. However, the company beat sales estimates with $1.74 billion, a 10.61% increase from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

June 04, 2024 | 11:31 am